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Mucocutaneous leishmaniasis: mucosal manifestations in an endemic
country
Figure 1. (A) Ulcerative lesion on the hard and soft palate. (B) Large erythematous lesion with an elevated, ulcerated, reddish surface, and irregular margins involving the hard
and soft palate and oropharynx. (C) Extensive lesion with marginal granulation tissue and a necrotic center. (D) Ulceration with granulomatous surface on the hard and soft
palate. (E) Multiple ulcerated nodules on the soft palate extending to the oropharynx. (F) Ulcerated lesion with a granular surface on the hard and soft palate.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j idWe report six cases of mucocutaneous leishmaniasis affecting
the oral mucosa. At the time of diagnosis, the age of the patients
ranged from 38 to 76 years, with a mean of 58.2 years. Five
patients were male and one female. Five patients were rural
workers. All patients reported cutaneous manifestations. The
lesions were found on the face, arms, legs, and nipple. Mucosal
disease took the form of large ulcers with a granulomatous aspect
and was most commonly found in the palate, followed by the
oropharynx. The hard and/or soft palate was affected in all cases,
the oropharynx in three cases, the nasal mucosa in ﬁve, and the
larynx in one case (Figure 1). Pain was the most common symptom
reported by patients and started a mean of 3 months before
diagnosis.
Microscopically there was predominance of a diffuse histiocytic
proliferation with scattered plasma cells and features vaguely
resembling granulomata. Small intracytoplasmic structures were
identiﬁed within macrophages by hematoxylin and eosin staining.
Only one patient was positive for anti-HIV serology. Parasitological
tests conﬁrmed the diagnosis of mucocutaneous leishmaniasis in
all cases. Species identiﬁcation was performed in four cases by PCR
using primers that speciﬁcally amplify kinetoplast DNA minicircles
belonging to the species Leishmania (Viannia) braziliensis, L. (V.)
guyanensis, and L. (L.) amazonensis directly from biological samples.1201-9712/$36.00 – see front matter  2013 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2013.05.013Three cases were identiﬁed as L. braziliensis and another as L.
guyanensis.
Five patients received intravenous infusions of liposomal
amphotericin B at 3 mg/kg/day for 14 days. In one case the
treatment was provided in the form of intramuscular injection of
meglumine antimoniate 15 mg/kg/day for 20 days. The HIV-
positive patient died 3 months after the diagnosis of leishmaniasis;
the other cases were considered cured after different periods of
follow-up.
Mucocutaneous leishmaniasis is endemic to regions of Latin
America, where the causative protozoan is L. braziliensis, or, rarely,
L. amazonensis or L. guyanensis.1–3 Leishmania promastigotes can
be isolated from the patients both by culture or animal
inoculation.2
In summary, it is important to emphasize that, although
uncommon, leishmaniasis can affect the oral mucosa and it can be
the ﬁrst sign of the disease.
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